Back to search

Article

Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade

2023-10-08

Abstract excerpt

175,000 patients die because of renal cell carcinoma (RCC) each year. Clear cell renal cell carcinoma (ccRCC or KIRC) is the most frequent subtype of RCC. Current therapies include immune checkpoint inhibitors (ICB) or VEGFR tyrosine kinase inhibitors (TKIs). However, many patients did not respond to ICB and immune resistance still occurred. Immune resistance may be explained by expression of various immune checkp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0dcf7da3-4796-5ef6-9f70-6c198e45425b
DOI
10.1101/2023.10.05.561140
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockadeDOI 10.1101/2023.10.05.561140
Select a neighboring publication to make it the new centre.